Ronaldo Holgado, DPM
Primary Podiatric Medicine · Surprise, AZNPI 1801849468
Payments from drug & device makers
What this record shows
Mimedx Group, Inc. accounts for 67.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $1,665 and has fallen 92.8% since, to $120 in 2025.
Across 30 payments — averaging $75.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mimedx Group, Inc.$2K
- Amgen$282
- KCI USA, Inc.$117
- Smith+Nephew$93
- AbbVie$93
- Orthofix Medical, Inc.$77
- plus $74 from 2 others
What the payments were for
- Travel & lodging$1,19953%
- Food & beverage$1,07747%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mimedx Group, Inc. | 6 | $1,542 |
| Amgen(2 entities) | 5 | $282 |
| KCI USA, Inc. | 2 | $117 |
| Smith+Nephew | 4 | $93 |
| AbbVie | 5 | $93 |
| Orthofix Medical, Inc. | 6 | $77 |
| Medtronic | 1 | $52 |
| Solventum Corporation | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$250
How this compares
Too few primary podiatric medicine providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciclopirox | 294 | $7,901 |
| Terbinafine Hcl | 145 | $1,334 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 25 | $907 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 29 | $362 |
| Methylprednisolone | 41 | $258 |
| Doxycycline Hyclate | 22 | $237 |
| Meloxicam | 64 | $173 |
| Cephalexin | 27 | $169 |
Paid to pharmacies, not to this prescriber.
Other primary podiatric medicine in Surprise
- Sanford KanerSurprise$20
- Warren JosephPhoenix$529K
- Zeno PfauTucson$5K
- David CorcoranPhoenix$4K
- Naresh DugalScottsdale$3K
- Brian HutchesonTucson$902
- Ruth KosakScottsdale$333
- Jean KroynCottonwood$306
- Stephen GellerPhoenix$78
- Phillip TutnauerPinon$36
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.